» Articles » PMID: 38859970

Metacognitive Accuracy Differences in Parkinson's Disease and REM Sleep Behavioral Disorder Relative to Healthy Controls

Overview
Journal Front Neurol
Specialty Neurology
Date 2024 Jun 11
PMID 38859970
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Metacognition is the ability to monitor and self-assess cognitive performance. It can be impaired in neurodegenerative diseases, with implications for daily function, and the ability of patients to reliably report their symptoms to health professionals. However, metacognition has not been systematically assessed in early-mid stage Parkinson's disease (PD) and REM sleep behavioral disorder (RBD), a prodrome of PD.

Objectives: This study aimed to evaluate metacognitive accuracy and self-confidence in PD and RBD patients across various cognitive tasks.

Methods: We conducted detailed computerized cognitive assessments with 19 cognitive tasks within an established PD and RBD cohort. Participants self-rated their performance post-task. Metacognitive accuracy was calculated by comparing these ratings against objective performance and further analyzed against clinical and mental health factors.

Results: PD and RBD patients' metacognitive accuracy aligned with control subjects. However, they exhibited lower confidence across cognitive domains, reflecting their reduced cognitive performance. A notable inverse correlation was observed between their confidence and MDS-UPDRS I and II scales and HADS anxiety and depression scores.

Conclusion: Our findings indicate that patients with early to mid-stage PD and RBD are generally aware of their cognitive status, differing from other neurological disorders. The inverse relationship between patient confidence and symptoms of depression, anxiety, and daily life challenges underscores the impact of emotional and functional difficulties on their self-perception of cognitive abilities. This insight could be significant for understanding how these conditions affect mental health, aiding clinicians in developing more effective patient care strategies.

Citing Articles

Remote cognitive tests predict neurodegenerative biomarkers in the Insight 46 cohort.

Giovane M, Giunchiglia V, Cai Z, Leoni M, Street R, Lu K Alzheimers Dement. 2025; 21(2):e14572.

PMID: 39936232 PMC: 11815243. DOI: 10.1002/alz.14572.


From mechanisms to future therapy: a synopsis of isolated REM sleep behavior disorder as early synuclein-related disease.

Stefani A, Antelmi E, Arnaldi D, Arnulf I, During E, Hogl B Mol Neurodegener. 2025; 20(1):19.

PMID: 39934903 PMC: 11817540. DOI: 10.1186/s13024-025-00809-0.

References
1.
Fahn S . Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003; 991:1-14. DOI: 10.1111/j.1749-6632.2003.tb07458.x. View

2.
Oh-Lee J, Szymkowicz S, Smith S, Otani H . Metacognitive Performance, the Tip-of-Tongue Experience, Is Not Disrupted in Parkinsonian Patients. Parkinsons Dis. 2012; 2012:174079. PMC: 3347746. DOI: 10.1155/2012/174079. View

3.
Fantini M, Farini E, Ortelli P, Zucconi M, Manconi M, Cappa S . Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder. Sleep. 2011; 34(5):619-25. PMC: 3079941. View

4.
Fleming S, Ryu J, Golfinos J, Blackmon K . Domain-specific impairment in metacognitive accuracy following anterior prefrontal lesions. Brain. 2014; 137(Pt 10):2811-22. PMC: 4163038. DOI: 10.1093/brain/awu221. View

5.
Goldstein F, Ashley A, Miller E, Alexeeva O, Zanders L, King V . Validity of the montreal cognitive assessment as a screen for mild cognitive impairment and dementia in African Americans. J Geriatr Psychiatry Neurol. 2014; 27(3):199-203. DOI: 10.1177/0891988714524630. View